AzTrials
AzTrials

FatigueEarly Phase 1NCT03051646

Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis

A Early Phase 1 study of Fatigue and Overheating, run by Columbia University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Exercise has many benefits for people with multiple sclerosis (MS), such as improved physical symptoms, mood, fatigue, and cognition. However, many people with MS refrain from exercising because of the discomfort of exhaustion and overheating that they experience. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Fatigue, Overheating
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
12 participants
Where
1 siteUnited States
Study dates
13 Jan 2017to 10 May 2017
Phase
Early Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • RRMS
  • self report of overheating during exercise
  • low physical disability (EDSS total score 4.5 or less); fully ambulatory without aid
  • exacerbation-free (and no use of corticosteroids) for 6 weeks prior
  • BMI 35 or lower

Who cannot join

  • uncontrolled hypertension or vascular disease of the legs
  • current medications for heart or blood pressure problem
  • prior history of head injury, stroke, or other neurological disease/disorder
  • currently taking antipyretics or pain medication daily
  • presence of major depressive disorder or other psychiatric diagnosis
  • formally diagnosed sleep disorder
Show all 10Show fewer
  • pulmonary disease, heart disease or other heart problem
  • diabetes mellitus or problem with blood sugar levels
  • lower body weakness or reliance on supportive devices for walking (as indicated through EDSS)
  • counter indications to aspirin use: history of confirmed peptic ulcer, gastrointestinal or sever gynecological bleeding; tarry stool or fecal occult blood; syndrome of asthma, rhinitis or nasal polyps

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Columbia University Medical Center, MS Center

    New York, New York, 10032

Other trials in United States

About this study

Official title: A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis

Exercise has many benefits for people with multiple sclerosis (MS), such as improved physical symptoms, mood, fatigue, and cognition. However, many people with MS refrain from exercising because of the discomfort of exhaustion and overheating that they experience. This study investigates the use of aspirin before exercise as a treatment to reduce overheating and exhaustion, thereby availing many more people with MS the opportunity to benefit from exercise.

The investigators recently published the first-ever report of elevated body temperature in relapsing-remitting MS (RRMS) patients relative to healthy controls, and elevated temperature was linked to worse fatigue. This finding that body temperature is elevated and linked to fatigue in RRMS lays the groundwork for a paradigm shift in our understanding and treatment of fatigue. That is, the focus shifts from exogenous to endogenous temperature, and from stimulant medication to cooling treatments.

A recent study comparing healthy adults to adults with MS showed that whereas exercise increased body temperature in both groups, only in the MS group was it correlated with exhaustion. The reason for this may relate to the elevation in resting body temperature in relapsing-remitting MS (RRMS) patients relative to healthy controls. The finding is clinically meaningful, as elevated body temperature was correlated with worse fatigue in patients. Exercise Aim: To determine whether pretreatment with ASA (compared to placebo: within subject crossover design) before exercise results in improved exercise performance (i.e., increased time-to-exhaustion). The investigators hypothesize that participants will tolerate exercise for longer after taking ASA than placebo. This hypothesis is based on a) demonstrated efficacy of antipyretic for reducing body temperature during exercise in healthy controls, b) demonstrated efficacy of antipyretic for reducing fatigue in non-exercising MS patients, and c) demonstrated efficacy of elaborate (unblinded) cooling treatments (e.g., cooling garments, cooling hand chamber) for improving exercise performance in MS patients. Note that this project is especially important for MS patients, who have a disease-specific body temperature elevation and sensitivity to heat (i.e., Uhthoff's).

Read the detailed description

Exercise is beneficial for people with MS. Exercise has many benefits for persons with multiple sclerosis (MS), including increased muscle strength, improved balance, decreased fatigue, decreased depression, improved memory, and improved quality of life. In addition to clinical improvements, there is direct and indirect neural evidence for beneficial effects of exercise in MS. For example, work in the experimental autoimmune encephalopathy (EAE) animal model of MS has shown that exercise protects against demyelination, increases brain-derived neurotrophic factor (BDNF), and reduces myelin damage and axonal damage. Consistent with pre-clinical research, MS work in humans has shown increased BDNF and reduction in pro-inflammatory circulating cytokines (i.e., IL-22) in those who exercised for 24 weeks versus those who maintained a sedentary lifestyle over the same period of time. In preliminary MS work from our group, 12 weeks of aerobic exercise resulted in increased hippocampal volume and hippocampal functional connectivity. Exercise is being considered as a candidate disease-modifying treatment. However, exercise is only beneficial if people do it. Despite the preponderance of evidence for exercise's salutary effects, many MS patients are deterred by overheating and exhaustion brought about by exercise. And while there is good evidence for the long-term safety profile of exercise in MS, many patients are put off by short-term discomforts, despite being physically capable of exercising.

Exercise causes overheating in people with MS. In healthy people, exercise triggers the conversion of metabolic to mechanical energy, resulting in the liberation of approximately 30-70% of the total energy as heat, which causes an increase in core body temperature. As core body temperature increases, exercise performance worsens. Exercise in persons with MS also raises body temperature, and heat-related MS symptoms increase following exercise. This is consistent with Uhthoff's phenomenon: the well-known deleterious impact of heat exposure and exercise for persons with MS. The investigators recently added an essential piece to this puzzle, reporting for the very first time that persons with relapsing-remitting MS (RRMS) have elevated body temperature even before being exposed to heat or exercising (i.e., at rest) relative to healthy controls. Importantly, this elevation in body temperature is clinically meaningful as warmer resting body temperature is linked to worse fatigue in patients with RRMS.Not only does this finding represent a paradigm shift in the conceptualization of heat sensitivity / heat exposure in persons with MS, but it highlights the additional burden of exercise-induced heat for people who are already warmer before exercise begins. Exercise increases body temperature in everyone; however, it was recently reported that only for persons with MS (compared to healthy controls) is exercise-induced increase in body temperature linked to exhaustion. Elevated body temperature at rest in persons with RRMS may be a key reason for this, and may also point to cooling as an effective treatment.

Cooling treatments are effective for people with MS. Elevated body temperature and its link to worse fatigue in RRMS patients aligns with positive results of several non-exercise trials of cooling treatments for reducing fatigue in MS patients none of which considered or targeted endogenously elevated body temperature. Aligned with this is evidence showing that cooling treatments administered to MS patients prior to or during exercise improve performance and reduce exhaustion. For example, in one study, ten MS patients used a hand-cooling chamber while walking on a treadmill: subjects kept one hand in the airtight device, a rigid chamber suspended by a bungee cord from above the treadmill throughout exercise. Cooling resulted in 33% increased exercise duration in the MS patients who kept their hand in the chamber. These findings support a beneficial impact of cooling during exercise, although these methods may be difficult to replicate / standardize, and implement clinically. In other work, whole-body precooling with a cooling vest and cap was used to successfully decrease perceived exertion during exercise. Yet another method of cooling via immersion in a cold water bath prior to exercise was found to reduce perceived exertion during exercise. By way of mechanism, Marino explained the heat-fatigue link in MS by proposing heat reaction blockade of action potentials in demyelinated neurons (i.e., frequency-dependent conduction block), noting that when demyelination is present, only a small increase in temperature (e.g., the amount induced by exercise) is necessary to completely block action potentials. This is consistent with seminal work in the giant squid axon demonstrating the disruption of action potentials in the presence of small, incremental increases in exogenous heat, ultimately resulting in reversible 'heat block' (cessation of neuronal conduction). An encouraging observation was that all effects of warming were completely reversible in this experimental model.

Cooling during exercise is an effective treatment for persons with RRMS. Taken together, the evidence supports cooling treatments as an effective means of improving exercise performance in patients with MS, although notably, no prior exercise study in MS has considered elevated core resting body temperature. Note that the finding of elevated body temperature was specific to RRMS; prior exercise cooling studies did not restrict their selection criteria to the relapsing-remitting phenotype. By doing so in the current proposal, the investigators expect to reveal a larger effect of cooling since relapsing-remitting MS patients with elevated body temperature at rest are most likely to experience exercise-induced fatigue (and are therefore most in need of effective cooling treatment). Prior methods of experimental cooling are cumbersome (e.g., cooling garments, immersion in a cool bath prior to exercise, insertion of one hand into a vacuum cooling chamber during exercise), thereby limiting replication and standardization for research use, and restricting practicality for clinical use. Here, the investigators propose to test the effectiveness of an oral antipyretic taken before exercise (i.e., administered 1-hour prior to exercise in order to reach peak serum concentration). Work in healthy adults has shown that antipyretic administration before exercise reduces body temperature during strenuous exercise in a hot environment, and improves performance (i.e., increases time-to-exhaustion). Aspirin (acetylsalicylic acid, ASA) has been selected, as it is shown to effectively reduce fatigue in prior non-exercise trials in MS (none of which considered aspirin's antipyretic mechanism of action as the key factor underlying treatment efficacy).

Conditions
Fatigue, Overheating
Being tested
Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit, Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit
Keywords
Exercise, Time to Exhaustion
Medical subject headings
Fatigue, Sunstroke, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Acetylsalicylic acid at 1st visit, then Placebo at 2nd visitDrug

    Also called aspirin, placebo

    650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise

  • Placebo at 1st visit, then Acetylsalicylic acid at 2nd visitDrug

    Also called placebo, aspirin

    Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise

Study groups in NCT03051646
Study groupRoleWhat they receive
Acetylsalicylic acid first, placebo secondExperimentalParticipant is administered acetylsalicylic acid one hour prior to exercise.
Receives: Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit
Placebo oral capsule first, ASA secondPlacebo comparatorParticipant is administered placebo one hour prior to exercise.
Receives: Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Time to Exhaustion

    The measure of interest is the length of time (in seconds) spent exercising at each session. This time has no pre-set upper limit, i.e. patients are free to exercise as long as they wish. This means that the time will not be censored. However, please note that healthy adults' time to exhaustion is approximately 12 minutes.

    Measured: ASA's effect will be assessed from date of randomization until cessation of exercise test at each of two study visits to be completed within a 14-day period.

Secondary outcomes (1)
  1. Exercise-induced Body Temperature Increase

    Measure of interest is increase in body temperature from pre- to post-exercise test in each treatment condition (ASA vs. placebo)

    Measured: Effect of treatment on body temperature in a single session (i.e., pre- to post- exercise test) to be completed within a 14-day period

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Feb 2017
  2. Study start13 Jan 2017
  3. Primary completion10 May 2017
  4. Study completion10 May 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Design is a within-subject crossover placebo-controlled experiment. Each participant will be seen for two exercise sessions (stationary cycling) on two days separated by one week, and will receive either ASA or placebo (treatment) at each session prior to commencing exercise. Order of treatment will be randomized and counter-balanced. As such, each participant will serve as his/her own control.
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03051646
Sponsor's protocol ID
AAAQ1758
Status last verified
Nov 2018
First submitted
8 Feb 2017
Last updated
20 Nov 2018
Data monitoring committee
No
FDA-regulated drug
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study of Fatigue and Overheating, run by Columbia University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Nov 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Time to Exhaustion (time frame: ASA's effect will be assessed from date of randomization until cessation of exercise test at each of two study visits to be completed within a 14-day period.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in